Management of Aromatase Inhibitor–Induced Arthralgia

J. Younus; L. Kligman

doi:10.3747/co.v17i1.474

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Article

1 February 2010

Management of Aromatase Inhibitor–Induced Arthralgia

and

790 Commissioners Road East, London, ON N6A 4L6, Canada

Author to whom correspondence should be addressed.

Curr. Oncol.2010, 17(1), 87-90;https://doi.org/10.3747/co.v17i1.474

Version Notes

Order Reprints

Abstract

Aromatase inhibitors (AIS) are commonly used as adjuvant treatment in postmenopausal women with hormone receptor–positive early breast cancer. With both steroidal and nonsteroidal AIS, AI-induced arthralgia is frequently observed. The mechanism of AI-induced arthralgia remains unknown, and the data available from clinical trails using AIS are limited. We review the pertinent information from a clinical perspective, including an algorithm to treat AI-induced arthralgia.

Keywords:

aromatase inhibitors; arthritis; arthralgia; breast cancer

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Management of Hot Flashes in Women with Breast Cancer

Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach